Fenofibrate enhances barrier function of endothelial continuum within the metastatic niche of prostate cancer cells

Bibliography

• Lamers C, Schubert-Zsilavecz M, Merk D. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present). Expert Opin Ther Pat 2012;22:803-41
   PubMed Web of Science ®Google Scholar
• Ahmed W, Ziouzenkova O, Brown J, et al. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med 2007;262:184-98
   PubMed Web of Science ®Google Scholar
• Grabacka M, Reiss K. Anticancer properties of PPARalpha-effects on cellular metabolism and inflammation. PPAR Res 2008;2008:930705
   Google Scholar
• Grabacka M, Pierzchalska M, Reiss K. Peroxisome proliferator activated receptor alpha ligands as anticancer drugs targeting mitochondrial metabolism. Curr Pharm Biotechnol 2013;14:342-56
   PubMed Web of Science ®Google Scholar
• Robinson JG. LDL reduction: how low should we go and is it safe? Curr Cardiol Rep 2008;10:481-7
   Google Scholar
• Adeghate E, Adem A, Hasan MY, et al. Medicinal chemistry and actions of dual and Pan PPAR modulators. Open Med Chem J 2011;5:93-8
   PubMedGoogle Scholar
• Balakumar P, Rohilla A, Mahadevan N. Pleiotropic actions of fenofibrate on the heart. Pharmacol Res 2011;63:8-12
   Google Scholar
• McKeage K, Keating GM. Fenofibrate: a review of its use in dyslipidaemia. Drugs 2011;71:1917-46
   PubMed Web of Science ®Google Scholar
• Katayama A, Yamamoto Y, Tanaka K, et al. Fenofibrate enhances neovascularization in a murine ischemic hindlimb model. J Cardiovasc Pharmacol 2009;54:399-404
   Google Scholar
• Hiukka A, Maranghi M, Matikainen N, et al. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 2010;6:454-63
   PubMed Web of Science ®Google Scholar
• Noonan JE, Jenkins AJ, Ma JX, et al. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes 2013;62:3968-75
   PubMed Web of Science ®Google Scholar
• Goetze S, Eilers F, Bungenstock A, et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 2002;293:1431-7
   PubMed Web of Science ®Google Scholar
• Varet J, Vincent L, Mirshahi P, et al. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci 2003;60:810-19
   Web of Science ®Google Scholar
• Meissner M, Stein M, Urbich C, et al. PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res 2004;94:324-32
   PubMedGoogle Scholar
• Panigrahy D, Kaipainen A, Huang S, et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 2008;105:985-90
   PubMed Web of Science ®Google Scholar
• Cao Z, Shang B, Zhang G, et al. Tumor cell-mediated neovascularization and lymphangiogenesis contrive tumor progression and cancer metastasis. Biochim Biophys Acta 2013;1836:273-86
   Google Scholar
• Hida K, Ohga N, Akiyama K, et al. Heterogeneity of tumor endothelial cells. Cancer Sci 2013;104:1391-5
   PubMed Web of Science ®Google Scholar
• Robison NJ, Campigotto F, Chi SN, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer 2014;61:636-42
   PubMed Web of Science ®Google Scholar
• Langley RR, Fidler IJ. The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011;128:2527-35
   PubMed Web of Science ®Google Scholar
• Giordano A, Macaluso M. Fenofibrate triggers apoptosis of glioblastoma cells in vitro: new insights for therapy. Cell Cycle 2012;11:3154
   PubMed Web of Science ®Google Scholar
• Jiao HL, Zhao BL. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol Appl Pharmacol 2002;185:172-9
   PubMed Web of Science ®Google Scholar
• Yamasaki D, Kawabe N, Nakamura H, et al. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARalpha-independent mechanisms. Eur J Cell Biol 2011;90:657-64
   Google Scholar
• Urbanska K, Pannizzo P, Grabacka M, et al. Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines. Int J Cancer 2008;123:1015-24
   PubMedGoogle Scholar
• Grabacka M, Plonka PM, Urbanska K, et al. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res 2006;12:3028-36
   PubMed Web of Science ®Google Scholar
• Grabacka M, Placha W, Plonka PM, et al. Inhibition of melanoma metastases by fenofibrate. Arch Dermatol Res 2004;296:54-8
   PubMed Web of Science ®Google Scholar
• Drukala J, Urbanska K, Wilk A, et al. ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha -mediated inhibition of Glioma cell notility in vitro. Mol Cancer 2010;9:159
   PubMedGoogle Scholar
• Wybieralska E, Szpak K, Gorecki A, et al. Fenofibrate attenuates contact-stimulated cell motility and gap junctional coupling in DU-145 human prostate cancer cell populations. Oncol Rep 2011;26:447-53
   PubMedGoogle Scholar
• Thuillier P, Anchiraico GJ, Nickel KP, et al. Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion. Mol Carcinog 2000;29:134-42
   PubMed Web of Science ®Google Scholar
• Saidi SA, Holland CM, Charnock-Jones DS, et al. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer 2006;5:13
   PubMedGoogle Scholar
• Panigrahy D, Kaipainen A, Kieran MW, et al. PPARs: a double-edged sword in cancer therapy? PPAR Res 2008;2008:350351
   PubMed Web of Science ®Google Scholar
• Scatena R, Bottoni P, Giardina B. Mitochondria, PPARs, and cancer: is receptor-independent action of PPAR agonists a key? PPAR Res 2008;2008:256251
   PubMed Web of Science ®Google Scholar
• Tomizawa A, Hattori Y, Inoue T, et al. Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism 2011;60:513-22
   PubMed Web of Science ®Google Scholar
• Reymond N, d’Agua BB, Ridley AJ. Crossing the endothelial barrier during metastasis. Nat Rev Cancer 2013;13:858-70
   PubMed Web of Science ®Google Scholar
• Wang X, Ferreira AM, Shao Q, et al. Beta3 integrins facilitate matrix interactions during transendothelial migration of PC3 prostate tumor cells. Prostate 2005;63:65-80
   PubMed Web of Science ®Google Scholar
• Woodward J. Crossing the endothelium: E-selectin regulates tumor cell migration under flow conditions. Cell Adh Migr 2008;2:151-2
   PubMed Web of Science ®Google Scholar
• Strell C, Niggemann B, Voss MJ, et al. Norepinephrine promotes the beta1-integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GROalpha release. Mol Cancer Res 2012;10:197-207
   PubMedGoogle Scholar
• Szpak K, Wybieralska E, Niedzialkowska E, et al. DU-145 prostate carcinoma cells that selectively transmigrate narrow obstacles express elevated levels of CX43. Cell Mol Biol Lett 2011;16:625-37
   Google Scholar
• Guan K, Czyz J, Furst DO, et al. Expression and cellular distribution of alpha(v)integrins in beta(1)integrin-deficient embryonic stem cell-derived cardiac cells. J Mol Cell Cardiol 2001;33:521-32
   Google Scholar
• Ryszawy D, Sarna M, Rak M, et al. Functional links between Snail-1 and Cx43 account for the recruitment of Cx43-positive cells into the invasive front of prostate cancer. Carcinogenesis 2014;35:1920-30
   Google Scholar
• Wojciak-Stothard B, Potempa S, Eichholtz T, et al. Rho and Rac but not Cdc42 regulate endothelial cell permeability. J Cell Sci 2001;114:1343-55
   PubMed Web of Science ®Google Scholar
• Miekus K, Czernik M, Sroka J, et al. Contact stimulation of prostate cancer cell migration: the role of gap junctional coupling and migration stimulated by heterotypic cell-to-cell contacts in determination of the metastatic phenotype of Dunning rat prostate cancer cells. Biol Cell 2005;97:893-903
   PubMed Web of Science ®Google Scholar
• Daniel-Wojcik A, Misztal K, Bechyne I, et al. Cell motility affects the intensity of gap junctional coupling in prostate carcinoma and melanoma cell populations. Int J Oncol 2008;33:309-15
   Google Scholar
• Quadri SK. Cross talk between focal adhesion kinase and cadherins: role in regulating endothelial barrier function. Microvasc Res 2012;83:3-11
   PubMed Web of Science ®Google Scholar
• Leesnitzer LM, Parks DJ, Bledsoe RK, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002;41:6640-50
   PubMed Web of Science ®Google Scholar
• Czyz J, Szpak K, Madeja Z. The role of connexins in prostate cancer promotion and progression. Nat Rev Urol 2012;9:274-82
   Google Scholar
• Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther 2014;141:150-9
   PubMed Web of Science ®Google Scholar
• van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res 2011;728:23-34
   PubMed Web of Science ®Google Scholar
• Pollmann MA, Shao Q, Laird DW, et al. Connexin 43 mediated gap junctional communication enhances breast tumor cell diapedesis in culture. Breast Cancer Res 2005;7:R522-34
   PubMed Web of Science ®Google Scholar
• Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011;147:992-1009
   PubMed Web of Science ®Google Scholar
• Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration during metastasis. Curr Opin Cell Biol 2012;24:277-83
   Google Scholar
• Garcia-Roman J, Zentella-Dehesa A. Vascular permeability changes involved in tumor metastasis. Cancer Lett 2013;335:259-69
   PubMed Web of Science ®Google Scholar
• Doser K, Guserle R, Nitsche V, et al. Comparative steady state study with 2 fenofibrate 250 mg slow release capsules. An example of bioequivalence assessment with a highly variable drug. Int J Clin Pharmacol Ther 1996;34:345-8
   Google Scholar
• Kajosaari LI, Backman JT, Neuvonen M, et al. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Clin Pharmacol 2004;58:390-6
   PubMed Web of Science ®Google Scholar
• Uetake D, Ohno I, Ichida K, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med 2010;49:89-94
   PubMed Web of Science ®Google Scholar
• Hu L, Wu H, Niu F, et al. Design of fenofibrate microemulsion for improved bioavailability. Int J Pharm 2011;420:251-5
   PubMed Web of Science ®Google Scholar
• Mroue RM, El Sabban ME, Talhouk RS. Connexins and the gap in context. Integr Biol (Camb) 2011;3:255-66
   PubMedGoogle Scholar
• Okayasu T, Tomizawa A, Suzuki K, et al. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci 2008;82:884-91
   PubMed Web of Science ®Google Scholar
• Alexander JS, Zhu Y, Elrod JW, et al. Reciprocal regulation of endothelial substrate adhesion and barrier function. Microcirculation 2001;8:389-401
   Google Scholar
• Deguchi S, Sato M. Biomechanical properties of actin stress fibers of non-motile cells. Biorheology 2009;46:93-105
   PubMed Web of Science ®Google Scholar
• Yuan SY, Shen Q, Rigor RR, et al. Neutrophil transmigration, focal adhesion kinase and endothelial barrier function. Microvasc Res 2012;83:82-8
   PubMed Web of Science ®Google Scholar
• Friedl P, Wolf K. Plasticity of cell migration: a multiscale tuning model. J Exp Med 2010;207:11-19
   Google Scholar
• Nevo I, Sagi-Assif O, Meshel T, et al. The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Cancer Lett 2009;273:127-39
   Google Scholar